{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:58:20Z","timestamp":1791028700992,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,7,10]],"date-time":"2006-07-10T00:00:00Z","timestamp":1152489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2006,7,10]],"date-time":"2006-07-10T00:00:00Z","timestamp":1152489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1007\/s10637-006-9208-z","type":"journal-article","created":{"date-parts":[[2006,7,10]],"date-time":"2006-07-10T21:43:35Z","timestamp":1152567815000},"page":"543-546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma"],"prefix":"10.1007","volume":"24","author":[{"given":"Ellen A.","family":"Ronnen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Varuni","family":"Kondagunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Ishill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"DeLuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Bacik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,7,10]]},"reference":[{"key":"9208_CR1","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1056\/NEJM199609193351207","volume":"335","author":"RJ Motzer","year":"1996","unstructured":"Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335:865\u2013875","journal-title":"N Engl J Med"},{"key":"9208_CR2","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Rini, BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, Bukoswki RM, George DJ, Kim ST, Baum CM (2005) Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). American Society of Clinical Oncology. vol. 23, Orlando, FL, p 380s","DOI":"10.1200\/jco.2005.23.16_suppl.4508"},{"key":"9208_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","volume":"24","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16\u201324","journal-title":"J Clin Oncol"},{"key":"9208_CR4","doi-asserted-by":"crossref","unstructured":"Ratain MJE, Stadler WM, Flaherty KT, Gore M, Desai A, Patnaik A, Xiong HQ, Schwartz B, O\u2019Dwyer P (2005) Final findings from a phase II placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). American Society of Clinical Oncology. vol. 23, no 16S, Orlando, FL, p 388s","DOI":"10.1200\/jco.2005.23.16_suppl.4544"},{"key":"9208_CR5","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1097\/01.ju.0000096060.92397.ed","volume":"170","author":"WM Linehan","year":"2003","unstructured":"Linehan WM, Walther MM, Zbar B (2003) The genetic basis of cancer of the kidney. J Urol 170:2163\u20132172","journal-title":"J Urol"},{"key":"9208_CR6","doi-asserted-by":"publisher","first-page":"29936","DOI":"10.1074\/jbc.M204733200","volume":"277","author":"JS Isaacs","year":"2002","unstructured":"Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277:29936\u201329944","journal-title":"J Biol Chem"},{"key":"9208_CR7","first-page":"2478","volume":"62","author":"NJ Mabjeesh","year":"2002","unstructured":"Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, Zhong H (2002) Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62:2478\u20132482","journal-title":"Cancer Res"},{"key":"9208_CR8","first-page":"342","volume":"60","author":"CP Webb","year":"2000","unstructured":"Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, Vande Woude GF (2000) The geldanamycins are potent inhibitors of the hepatocyte growth factor\/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 60:342\u2013349","journal-title":"Cancer Res"},{"key":"9208_CR9","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/sj.onc.1205184","volume":"21","author":"AD Basso","year":"2002","unstructured":"Basso AD, Solit DB, Munster PN, Rosen N (2002) Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21:1159\u20131166","journal-title":"Oncogene"},{"key":"9208_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/00001813-200404000-00011","volume":"15","author":"AM Burger","year":"2004","unstructured":"Burger AM, Fiebig HH, Stinson SF, Sausville EA (2004) 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 15:377\u2013387","journal-title":"Anticancer Drugs"},{"key":"9208_CR11","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1200\/JCO.2005.09.119","volume":"23","author":"MP Goetz","year":"2005","unstructured":"Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S, Adjei A, Croghan G, Erlichman C (2005) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23:1078\u20131087","journal-title":"J Clin Oncol"},{"key":"9208_CR12","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1200\/JCO.2005.12.085","volume":"23","author":"JL Grem","year":"2005","unstructured":"Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM, Neckers L, Wilson RH (2005) Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23:1885\u20131893","journal-title":"J Clin Oncol"},{"key":"9208_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"9208_CR14","doi-asserted-by":"publisher","first-page":"6393S","DOI":"10.1158\/1078-0432.CCR-040032","volume":"10","author":"WM Stadler","year":"2004","unstructured":"Stadler WM (2004) Therapeutic options for variant renal cancer: A true orphan disease. Clin Cancer Res 10:6393S\u20136396S","journal-title":"Clin Cancer Res"},{"key":"9208_CR15","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1038\/sj.onc.1202547","volume":"18","author":"L Schmidt","year":"1999","unstructured":"Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, Lubensky I, Neumann HP, Brauch H, Decker J, Vocke C, Brown JA, Jenkins R, Richard S, Bergerheim U, Gerrard B, Dean M, Linehan WM, Zbar B (1999) Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18:2343\u20132350","journal-title":"Oncogene"},{"key":"9208_CR16","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","volume":"17","author":"RJ Motzer","year":"1999","unstructured":"Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530\u20132540","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-006-9208-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-006-9208-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-006-9208-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-006-9208-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:19:00Z","timestamp":1678558740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-006-9208-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,10]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["9208"],"URL":"https:\/\/doi.org\/10.1007\/s10637-006-9208-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,10]]},"assertion":[{"value":"10 July 2006","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}